The approval from the U.S. Food and Drug Administration came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by itself, reduced the risk of disease progression or death by 58% in specific endometrial cancer patients, compared to chemotherapy alone, the Anglo-Swedish drugmaker said on Monday. "Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease," Dave Fredrickson, executive vice-president of the company's oncology business unit, said in a statement.
The CNN host reminded Sen. Tom Cotton of his prediction for how the former president would react to the 2020 election results.
Ukraine will be ones to watch at Euro 2024 as Serhiy Rebrov’s side begin their campaign in Munich against Romania